Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients. [electronic resource]
Producer: 20180828Description: 315-321 p. digitalISSN:- 1432-1041
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast -- drug effects
- Breast Neoplasms -- drug therapy
- Cohort Studies
- Cyclophosphamide -- adverse effects
- Docetaxel
- Doxorubicin -- adverse effects
- Febrile Neutropenia -- chemically induced
- Female
- Filgrastim -- therapeutic use
- Granulocyte Colony-Stimulating Factor -- therapeutic use
- Hematologic Agents -- therapeutic use
- Hospitals, University
- Humans
- Incidence
- Lenograstim
- Neoplasm Staging
- Pharmacoepidemiology -- methods
- Polyethylene Glycols -- therapeutic use
- Recombinant Proteins -- therapeutic use
- Retrospective Studies
- Risk Factors
- Severity of Illness Index
- Spain -- epidemiology
- Taxoids -- adverse effects
No physical items for this record
Publication Type: Equivalence Trial; Journal Article; Multicenter Study; Observational Study
There are no comments on this title.
Log in to your account to post a comment.